This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month this June.
First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at increased risk of progressing to severe stages of COVID-19
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.
Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer.
International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
We are Generation Cure. On June 11, we celebrated the ninth annual global immunotherapy awareness day to support a future immune to cancer.
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.